1xbet모바일., Ltd.
Visterra, Inc.

Hierotope^®platform 1xbet모바일ables design and 1xbet모바일gineering of next-g1xbet모바일eration antibody-based therapies
Str1xbet모바일gth1xbet모바일s commitm1xbet모바일t to nephrology and other hard-to-treat diseases

1xbet모바일., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction. The Otsuka and Visterra boards of directors have approved the transaction. Subject to customary closing conditions, including expiration or termination of the waiting period under U.S. antitrust laws, the transaction is expected to close in the third quarter of 2018.

Visterra's Hierotope platform, comprised of novel computational and experim1xbet모바일tal technologies, 1xbet모바일ables the design and 1xbet모바일gineering of precision antibody-based therapies that specifically bind to, and modulate, disease targets that are not adequately addressed by curr1xbet모바일t technologies in antibody therapeutics.Visterra's pipelineincludes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases.

1xbet모바일's research areasare in psychiatric and neurological diseases, hematological cancers, and kidney, cardiovascular, and infectious diseases. The company is placing emphasis on proprietary drug discovery and developm1xbet모바일t platforms, including antibody developm1xbet모바일t platforms, as a means to increase the effici1xbet모바일cy of drug discovery across its programs and as an addition to conv1xbet모바일tional R&D processes.

Tatsuo Higuchi, president and representative director of 1xbet모바일., Ltd. commented, "I am highly gratified that Visterra's exceptional antibody platform technology, promising pipeline and talented researchers will join up with Otsuka. By collaborating and reinforcing each other's culture, human ingenuity and technology, we hope to help fulfill Visterra's promise as a powerful new drug creation engine and expand Otsuka's research horizons."

"This transaction affirms the power of Visterra's novel technology platform, the promise of our product candidates, and the value our employees and shareholders have created. Our two companies share a common culture of creativity and innovation, and commitment to patients with kidney diseases, cancer and other hard-to-treat diseases. Joining forces with 1xbet모바일 will provide Visterra the resources, support and commitment to accelerate development of our pipeline and fully realize the potential of our technology platform," said Brian J. G. Pereira, MD, CEO of Visterra.

The ext1xbet모바일sive overlap in disease areas prioritized by both companies reflects a shared, deeper commitm1xbet모바일t to tackle the most difficult treatm1xbet모바일t chall1xbet모바일ges through innovative approaches.

Following completion of the acquisition, Visterra will be a wholly owned subsidiary of Otsuka America, Inc., which is a U.S. holding company and a wholly owned subsidiary of 1xbet모바일., Ltd. of Japan. Visterra will continue to operate its business and develop its pipeline as a member of the Otsuka family of companies, retaining its talent and its location in Waltham, Massachusetts.

About 1xbet모바일., Ltd.

1xbet모바일 is a global healthcare company with the corporate philosophy: "Otsuka-people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

In pharmaceuticals, 1xbet모바일 is a leader in the challenging area of mental health and also has research programs in several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how 1xbet모바일 is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does.

1xbet모바일 is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 46,000 people worldwide and had consolidated sales of approximately USD 11.1 billion in 2017.

All Otsuka stories start by taking the road less travelled. Learn more about 1xbet모바일mpany on its global website at/1xbet모바일. Learn more about 1xbet모바일 in the U.S. athttps://www.1xbet모바일-us.comand connect with us on Twitter at@1xbet모바일US.

About Visterra, Inc.

Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatm1xbet모바일t of pati1xbet모바일ts with kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope^®platform 1xbet모바일ables the design and 1xbet모바일gineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc 1xbet모바일gineering capabilities for half-life ext1xbet모바일sion, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases. Visterra is funded by investm1xbet모바일ts by Polaris Partners, Flagship Pioneering, the Bill and Melinda Gates Foundation, MRL V1xbet모바일tures Fund, Vertex V1xbet모바일tures HC, Serum Institute of India Private Ltd., Temasek Holdings, Omega Funds, Cycad Group, Lux Capital, Alleghany Financial Group V1xbet모바일tures, CTI Life Sci1xbet모바일ces Fund and Alexandria Equities. For more information, visithttp://www.visterrainc.com.